This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • HIV/AIDS  • Medical Practice  • Medical Practice, Other  • Renal Diseases  • Renal Diseases, Other  • Surgery  • Surgical Physiology  • Surgical Physiology, Other  • Transplantation  • Kidney Transplantation  • Women's Health  • Women's Health, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(10):1009-1010.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

More than 5 decades after the first successful kidney transplant, researchers continue to fine-tune the process, finding better ways to extend the survival of the transplanted organ and increase the likelihood of a compatible graft, as well as illuminate factors that affect who is offered the procedure.

Researchers have discovered polyomavirus aggregates called Haufen in urine samples that could serve as a nephropathy biomarker for patients with a transplanted kidney. (Photo credit: Volker Nickeleit, MD/University of North Carolina.)

Different groups of researchers recently have found a potentially easier method of predicting polyomavirus nephropathy in kidney recipients, which can result in chronic allograft failure or loss if it is not treated at an early stage. Other investigators created a set of nomograms to give physicians a fairly easy tool to weigh a multitude of factors to optimize a match between living donors and kidney recipients.

Yet another group of . . . [Full Text of this Article]

NEPHROPATHY



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?